Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate HighlightsGlobeNewsWire · Aug 11, 2026
Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)PRNewsWire · Aug 11, 2026Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.01 | -$0.01 | Beat |
| May 12, 2026 | $0.02 | -$0.01 | Miss |
| Mar 19, 2026 | -$0.01 | -$0.01 | Beat |
| Nov 10, 2025 | -$0.01 | -$0.01 | Miss |
| Aug 12, 2025 | -$0.01 | -$0.02 | Miss |
| May 13, 2025 | -$0.01 | -$0.02 | Miss |